Undifferentiated Symptoms — MCQs
On this page
A 39-year-old woman presents with an 11-week history of daily fever ranging from 38.5-39.2°C, occurring mainly in the evenings. She also reports arthralgia affecting multiple joints, a transient salmon-pink rash that appears with fever, and sore throat. Blood tests show WCC 16.8 × 10⁹/L (neutrophils 13.2 × 10⁹/L), Hb 108 g/L, platelets 456 × 10⁹/L, ESR 72 mm/hr, CRP 95 mg/L, ferritin 4850 μg/L, and negative ANA and rheumatoid factor. What is the most likely diagnosis?
A 63-year-old man with metastatic lung cancer presents with severe bone pain (8/10) from spinal metastases. He is currently taking morphine sulphate modified release 60mg twice daily and has been using 10mg immediate-release morphine for breakthrough pain approximately 8 times in the past 24 hours. His pain remains poorly controlled. What is the most appropriate adjustment to his analgesia regimen?
A 46-year-old woman presents with a 20-week history of fatigue and widespread pain affecting her neck, back, and limbs. Pain scores average 7/10 and are present most days. She reports poor sleep quality, waking unrefreshed. She has tried paracetamol and ibuprofen with minimal benefit. Examination shows multiple tender points but no joint swelling or muscle weakness. Blood tests including FBC, ESR, CRP, thyroid function, and vitamin D are all normal. She asks about starting amitriptyline. What is the most appropriate initial dose and dosing regimen?
A 72-year-old man presents with a 9-week history of fever (temperatures documented between 38.2-38.9°C), weight loss of 7kg, and progressive fatigue. He has a history of aortic valve replacement 3 years ago (mechanical valve) and is on warfarin. Three sets of blood cultures taken when febrile have shown no growth after 5 days. Echocardiogram shows the prosthetic valve functioning normally with no vegetations seen. CRP is 78 mg/L, ESR 62 mm/hr. What is the most appropriate next step in investigation?
A 35-year-old woman presents with a 14-week history of profound fatigue, low-grade fever, and a 6kg weight loss. She reports polyuria and polydipsia developing over the past 3 weeks. She appears tanned despite no recent sun exposure. Blood tests show Na+ 129 mmol/L, K+ 5.8 mmol/L, urea 8.2 mmol/L, glucose 2.8 mmol/L, and random cortisol 85 nmol/L. Which investigation is most important to arrange urgently?
According to current UK guidance on the management of chronic pain in primary care, which of the following is the recommended first-line pharmacological approach for chronic primary pain?
A 50-year-old woman presents with a 16-week history of progressive fatigue and generalised weakness. She reports feeling cold despite warm weather and has gained 4kg in weight. She has a past history of type 1 diabetes mellitus. Examination reveals delayed relaxation of ankle reflexes and dry skin. Blood tests show TSH 42 mIU/L (0.5-5.0), free T4 8 pmol/L (10-22), Hb 108 g/L, MCV 98 fL, and fasting glucose 8.2 mmol/L. Which additional autoimmune condition should be specifically screened for given this presentation?
A 41-year-old man presents with a 12-week history of fatigue, night sweats, and a 5kg weight loss. He reports intermittent fevers but has not documented his temperature. He travelled to India 6 months ago to visit family. Examination reveals palpable cervical lymphadenopathy measuring 2cm. Blood tests show Hb 118 g/L, WCC 9.8 × 10⁹/L (lymphocytes 6.2 × 10⁹/L), ESR 48 mm/hr, CRP 35 mg/L, normal liver and renal function. Chest X-ray shows bilateral hilar lymphadenopathy. What is the single most appropriate investigation to establish the diagnosis?
A 58-year-old woman presents with a 10-week history of unintentional weight loss of 8kg. She reports decreased appetite but denies dysphagia, abdominal pain, or altered bowel habit. She has no past medical history and takes no regular medications. Physical examination is unremarkable. Initial blood tests show Hb 132 g/L, WCC 7.2 × 10⁹/L, platelets 245 × 10⁹/L, ESR 18 mm/hr, CRP 6 mg/L, normal renal and liver function, normal thyroid function, and HbA1c 38 mmol/mol. What is the most appropriate next step in management?
Which of the following statements best describes the concept of 'diagnostic safety-netting' when managing patients with undifferentiated symptoms in primary care?
Undifferentiated Symptoms UK Medical PG Practice Questions and MCQs
Question 101: A 39-year-old woman presents with an 11-week history of daily fever ranging from 38.5-39.2°C, occurring mainly in the evenings. She also reports arthralgia affecting multiple joints, a transient salmon-pink rash that appears with fever, and sore throat. Blood tests show WCC 16.8 × 10⁹/L (neutrophils 13.2 × 10⁹/L), Hb 108 g/L, platelets 456 × 10⁹/L, ESR 72 mm/hr, CRP 95 mg/L, ferritin 4850 μg/L, and negative ANA and rheumatoid factor. What is the most likely diagnosis?
- A. Systemic lupus erythematosus
- B. Acute rheumatic fever
- C. Kikuchi-Fujimoto disease
- D. Adult-onset Still's disease (Correct Answer)
- E. Lymphoma with paraneoplastic phenomena
Explanation: ***Adult-onset Still's disease*** - Characterized by the classic triad of **high spiking quotidian fevers**, a **transient salmon-pink rash** that appears with fever, and **polyarthralgia**, all of which are present in this patient along with sore throat. - Key laboratory findings include **markedly elevated ferritin** (often >2500 μg/L), significant **neutrophilic leukocytosis**, elevated inflammatory markers (ESR, CRP), and the absence of **ANA** and **rheumatoid factor**. *Systemic lupus erythematosus* - While it can cause fever and arthralgia, SLE is typically associated with a **positive ANA** and other autoantibodies (e.g., anti-dsDNA), which are negative here. - The rash in SLE is commonly a persistent **malar rash** or discoid rash, differing from the evanescent, salmon-pink rash described. *Acute rheumatic fever* - This condition typically follows a **Group A streptococcal pharyngitis** and presents with **migratory polyarthritis** and elevated inflammatory markers, but not the extreme hyperferritinemia seen. - The characteristic rash is **erythema marginatum**, which has distinct erythematous borders and central clearing, unlike the transient maculopapular rash of Still's disease. *Kikuchi-Fujimoto disease* - Primarily presents with **painful cervical lymphadenopathy** and fever, often without the profound systemic inflammatory response, significant arthralgia, or the distinctive rash of Still's disease. - It does not typically feature the prominent **neutrophilic leukocytosis** or the specific **evanescent salmon-pink maculopapular rash** and extreme hyperferritinemia found in this patient. *Lymphoma with paraneoplastic phenomena* - Can present with **B-symptoms** (fever, weight loss, night sweats) and elevated inflammatory markers, but usually involves **lymphadenopathy** or splenomegaly, and often lacks the specific rash. - While ferritin can be elevated in malignancies, it rarely reaches the **extreme levels** observed (4850 μg/L) with the characteristic **fever-rash synchronization** seen in Adult-onset Still's disease.
Question 102: A 63-year-old man with metastatic lung cancer presents with severe bone pain (8/10) from spinal metastases. He is currently taking morphine sulphate modified release 60mg twice daily and has been using 10mg immediate-release morphine for breakthrough pain approximately 8 times in the past 24 hours. His pain remains poorly controlled. What is the most appropriate adjustment to his analgesia regimen?
- A. Add gabapentin 300mg three times daily to current opioid regimen
- B. Increase modified-release morphine to 90mg twice daily and breakthrough dose to 15-18mg (Correct Answer)
- C. Continue current modified-release dose and increase breakthrough dose to 20mg
- D. Switch to transdermal fentanyl patch 50 micrograms/hour with morphine breakthrough
- E. Increase modified-release morphine to 80mg twice daily and keep breakthrough dose at 10mg
Explanation: ***Increase modified-release morphine to 90mg twice daily and breakthrough dose to 15-18mg*** - The patient's total daily morphine consumption is **200mg** (120mg background + 80mg breakthrough), indicating that the current background dose is inadequate for his **metastatic bone pain**. - When adjusting doses, the new **daily background dose** should reflect the previous 24-hour total, and the **breakthrough dose** should be **1/6th to 1/10th** of the total daily dose (180mg/6 = 30mg, or 1/10th being 18mg). *Add gabapentin 300mg three times daily to current opioid regimen* - While **gabapentin** is useful for **neuropathic pain**, the immediate priority is to stabilize the **opioid titration** for a patient using frequent breakthrough doses. - Adding an adjuvant doesn't address the primary failure of the current **morphine regimen** to provide baseline analgesia. *Continue current modified-release dose and increase breakthrough dose to 20mg* - Increasing only the **breakthrough dose** fails to address the underlying issue that the **modified-release dose** is too low to maintain steady-state pain control. - Relying on PRN medication for **background pain** leads to a "peak-and-trough" effect, resulting in poor symptom management. *Switch to transdermal fentanyl patch 50 micrograms/hour with morphine breakthrough* - **Fentanyl patches** are generally reserved for patients with **stable pain** requirements or those unable to tolerate oral medications. - Switching an unstable patient to a **transdermal delivery** system makes rapid dose titration difficult and carries a risk of **unpredictable absorption**. *Increase modified-release morphine to 80mg twice daily and keep breakthrough dose at 10mg* - A breakthrough dose should always be **proportionally increased** as the background dose increases to remain effective (typically **1/6th of the total daily dose**). - Keeping the breakthrough at **10mg** while increasing the background provides a dose that is clinically insufficient compared to the patient's demonstrated **daily requirements**.
Question 103: A 46-year-old woman presents with a 20-week history of fatigue and widespread pain affecting her neck, back, and limbs. Pain scores average 7/10 and are present most days. She reports poor sleep quality, waking unrefreshed. She has tried paracetamol and ibuprofen with minimal benefit. Examination shows multiple tender points but no joint swelling or muscle weakness. Blood tests including FBC, ESR, CRP, thyroid function, and vitamin D are all normal. She asks about starting amitriptyline. What is the most appropriate initial dose and dosing regimen?
- A. 25mg at night, increasing by 25mg every 2 weeks to target dose of 75mg
- B. 50mg at night as a single starting dose given the severity of symptoms
- C. 10mg at night, increasing by 10mg weekly to a maximum of 75mg
- D. 10mg at night, reviewing after 4 weeks before considering dose increase (Correct Answer)
- E. 10mg three times daily, converting to once-daily dosing after 2 weeks
Explanation: ***10mg at night, reviewing after 4 weeks before considering dose increase*** - For **fibromyalgia** and chronic primary pain, **low-dose amitriptyline** (starting at 10mg) is used for its **analgesic** and **sleep-modulating** properties, rather than its antidepressant effect. - A **review after 4 weeks** is crucial to assess clinical response and manage potential side effects, ensuring the patient tolerates the medication before any dose increase. *25mg at night, increasing by 25mg every 2 weeks to target dose of 75mg* - Starting at **25mg** is often too high for initial pain management and significantly increases the risk of **anticholinergic side effects** and **sedation**. - Rapidly escalating to **75mg** is generally unnecessary, as many patients achieve symptom control at much lower doses, typically between **10mg and 30mg**. *50mg at night as a single starting dose given the severity of symptoms* - A starting dose of **50mg** is inappropriate for chronic pain and would likely lead to severe **sedation**, **dizziness**, and **dry mouth**, resulting in poor compliance. - Symptom severity in fibromyalgia does not justify bypassing the "**start low, go slow**" principle essential for titrating tricyclic antidepressants to minimize adverse effects. *10mg at night, increasing by 10mg weekly to a maximum of 75mg* - While the **10mg starting dose** is correct, a **weekly increase** is generally too aggressive and does not allow enough time to assess the full therapeutic benefit and tolerability of each dose level. - Routine titration up to **75mg** is not standard practice for fibromyalgia; the goal is the **lowest effective dose** to minimize side effects, which is often much lower. *10mg three times daily, converting to once-daily dosing after 2 weeks* - **Three times daily dosing** is not recommended for amitriptyline in this context due to its significant sedative properties, which would cause excessive daytime **somnolence**. - **Once-daily dosing at night** is preferred to utilize the medication's sedative effects to improve **sleep quality**, a core symptom of fibromyalgia, without causing daytime impairment.
Question 104: A 72-year-old man presents with a 9-week history of fever (temperatures documented between 38.2-38.9°C), weight loss of 7kg, and progressive fatigue. He has a history of aortic valve replacement 3 years ago (mechanical valve) and is on warfarin. Three sets of blood cultures taken when febrile have shown no growth after 5 days. Echocardiogram shows the prosthetic valve functioning normally with no vegetations seen. CRP is 78 mg/L, ESR 62 mm/hr. What is the most appropriate next step in investigation?
- A. Request extended culture of blood samples for fastidious organisms
- B. Arrange urgent transoesophageal echocardiogram (Correct Answer)
- C. Arrange whole-body FDG-PET-CT scanning
- D. Commence empirical antibiotic therapy for culture-negative endocarditis
- E. Arrange CT chest, abdomen and pelvis with contrast
Explanation: ***Arrange urgent transoesophageal echocardiogram*** - A **transoesophageal echocardiogram (TOE)** is the investigation of choice for **prosthetic valve endocarditis (PVE)** because it has significantly higher sensitivity (90-95%) compared to transthoracic echocardiography (TTE), which is often limited by **acoustic shadowing** from the mechanical valve. - Given the patient's **fever of unknown origin (FUO)** and high-risk prosthetic valve history, a negative TTE does not rule out infection, and TOE is necessary to detect **vegetations, abscesses, or dehiscence**. *Request extended culture of blood samples for fastidious organisms* - While **culture-negative endocarditis** can be caused by fastidious **HACEK organisms** or Coxiella, modern blood culture systems usually detect most organisms within 5 days. - This step should happen in parallel with imaging but does not take precedence over a **TOE** to visualize the prosthetic valve anatomy and potential damage. *Arrange whole-body FDG-PET-CT scanning* - **FDG-PET/CT** is increasingly used in the **Modified Duke Criteria** for prosthetic valves, but it is typically reserved for cases where TOE remains inconclusive or to identify metastatic infection. - It is not the first-line imaging modality when **infective endocarditis** is clinically suspected, as TOE provides superior anatomical detail and immediate results. *Commence empirical antibiotic therapy for culture-negative endocarditis* - Empirical antibiotics should be deferred until essential diagnostic workup, including **TOE**, is performed to avoid suppressing culture yields or masking diagnostic findings. - Starting treatment without a confirmed diagnosis or further imaging is premature in a **hemodynamically stable** patient with a complex clinical presentation. *Arrange CT chest, abdomen and pelvis with contrast* - A **CT CAP** is often a standard part of a **pyrexia of unknown origin (PUO)** workup to look for occult malignancy or abscesses. - However, in a patient with a **mechanical heart valve**, the clinical suspicion for **endocarditis** remains the highest priority, making TOE the mandatory next structural investigation.
Question 105: A 35-year-old woman presents with a 14-week history of profound fatigue, low-grade fever, and a 6kg weight loss. She reports polyuria and polydipsia developing over the past 3 weeks. She appears tanned despite no recent sun exposure. Blood tests show Na+ 129 mmol/L, K+ 5.8 mmol/L, urea 8.2 mmol/L, glucose 2.8 mmol/L, and random cortisol 85 nmol/L. Which investigation is most important to arrange urgently?
- A. Magnetic resonance imaging of pituitary gland
- B. CT chest, abdomen and pelvis to exclude malignancy
- C. Short Synacthen stimulation test (Correct Answer)
- D. 21-hydroxylase antibodies and adrenal antibodies
- E. Insulin tolerance test to assess HPA axis
Explanation: ***Short Synacthen stimulation test*** - The patient's presentation with profound fatigue, weight loss, **hyperpigmentation** (tanned appearance), **hyponatremia**, **hyperkalemia**, **hypoglycemia**, and a low random **cortisol** (85 nmol/L) is highly suggestive of **primary adrenal insufficiency** (Addison's disease). The Short Synacthen test is the gold standard for confirming this diagnosis. - This test directly assesses the **adrenal gland's ability** to produce cortisol in response to synthetic **ACTH**, providing immediate diagnostic clarity for urgent management. *Magnetic resonance imaging of pituitary gland* - MRI of the pituitary gland is primarily used to investigate **secondary adrenal insufficiency**, where the pathology lies in the pituitary or hypothalamus, leading to **low ACTH** production. - The patient's **hyperpigmentation** and **hyperkalemia** strongly indicate **primary adrenal insufficiency**, where ACTH levels are high due to adrenal failure, making pituitary imaging a less urgent initial step. *CT chest, abdomen and pelvis to exclude malignancy* - While conditions like **tuberculosis** or **metastatic cancer** can cause adrenal destruction, confirming the **functional deficiency** of the adrenal gland with a stimulation test is the immediate priority. - Imaging to find the underlying etiology is a secondary step after biochemical confirmation of adrenal insufficiency, and it is not as urgent as confirming the diagnosis itself. *21-hydroxylase antibodies and adrenal antibodies* - These tests are valuable for determining the **etiology** of primary adrenal insufficiency, specifically identifying an **autoimmune cause**. - However, they do not establish the diagnosis of adrenal insufficiency itself; the functional status of the adrenal gland must first be confirmed with a **dynamic stimulation test**. *Insulin tolerance test to assess HPA axis* - The **Insulin Tolerance Test (ITT)** induces hypoglycemia to assess the **hypothalamic-pituitary-adrenal (HPA) axis** and is contraindicated in this patient. - The patient already has symptomatic **hypoglycemia (glucose 2.8 mmol/L)**, making the ITT dangerous and risking severe adverse events like seizures or coma.
Question 106: According to current UK guidance on the management of chronic pain in primary care, which of the following is the recommended first-line pharmacological approach for chronic primary pain?
- A. Paracetamol with or without a weak opioid such as codeine
- B. A tricyclic antidepressant such as amitriptyline (Correct Answer)
- C. A selective serotonin reuptake inhibitor such as duloxetine
- D. A non-steroidal anti-inflammatory drug with gastric protection
- E. Gabapentin or pregabalin titrated to therapeutic dose
Explanation: ***A tricyclic antidepressant such as amitriptyline*** - According to **NICE NG193** guidelines, antidepressants like **amitriptyline** are recommended for the management of **chronic primary pain** (e.g., fibromyalgia) in adults. - This pharmacological intervention should only be considered if non-pharmacological therapies, such as **exercise programmes** or **psychological therapies**, have been discussed. *Paracetamol with or without a weak opioid such as codeine* - Current guidance specifically recommends **against** the use of **paracetamol** or **opioids** for chronic primary pain due to lack of evidence for efficacy and risk of harm. - **Opioids** are associated with serious long-term risks, including **dependence** and **opioid-induced hyperalgesia**. *A selective serotonin reuptake inhibitor such as duloxetine* - While some antidepressants are recommended, **Duloxetine** is technically a **Serotonin-Noradrenaline Reuptake Inhibitor (SNRI)**, not an SSRI, making this option pharmacologically inaccurate. - While **SNRIs** can be used for pain, the primary choice among antidepressants listed in guidelines often highlights **tricyclics** or specific SNRIs when appropriate. *A non-steroidal anti-inflammatory drug with gastric protection* - **NICE** guidelines recommend **against** the initiation of **NSAIDs** for chronic primary pain because there is little evidence they improve quality of life or pain levels long-term. - Their use is generally restricted to **chronic secondary pain** conditions where there is an underlying inflammatory or structural cause. *Gabapentin or pregabalin titrated to therapeutic dose* - These **anti-epileptics** are recommended for **neuropathic pain**, but the latest guidance specifically advises **against** their use for chronic primary pain. - There is an increased concern regarding the risk of **misuse**, **dependence**, and lack of long-term benefit for non-neuropathic primary pain syndromes.
Question 107: A 50-year-old woman presents with a 16-week history of progressive fatigue and generalised weakness. She reports feeling cold despite warm weather and has gained 4kg in weight. She has a past history of type 1 diabetes mellitus. Examination reveals delayed relaxation of ankle reflexes and dry skin. Blood tests show TSH 42 mIU/L (0.5-5.0), free T4 8 pmol/L (10-22), Hb 108 g/L, MCV 98 fL, and fasting glucose 8.2 mmol/L. Which additional autoimmune condition should be specifically screened for given this presentation?
- A. Primary biliary cholangitis
- B. Sjögren's syndrome
- C. Coeliac disease
- D. Addison's disease (Correct Answer)
- E. Pernicious anaemia
Explanation: ***Addison's disease*** - This patient likely has **Autoimmune Polyglandular Syndrome type 2 (APS-2)**, characterized by the triad of **Type 1 Diabetes Mellitus**, autoimmune thyroid disease (hypothyroidism), and **Addison's disease**. - Screening for **primary adrenal insufficiency** is critical because starting thyroxine in an undiagnosed Addison's patient can precipitate a life-threatening **adrenal crisis** by increasing metabolic cortisol clearance. *Coeliac disease* - While associated with **Type 1 Diabetes**, it typically presents with gastrointestinal symptoms, malabsorption, or iron deficiency rather than the classic APS-2 triad. - Primary hypothyroidism and fatigue in this context are more directly linked to the autoimmune endocrine cluster. *Pernicious anaemia* - This can cause **macrocytic anaemia** and fatigue (as seen with this patient's MCV of 98 fL), but it is not a defining component of the core **Schmidt’s syndrome (APS-2)** triad. - The priority screening in polyendocrine failure remains the adrenal axis to avoid clinical catastrophe during treatment of other glands. *Primary biliary cholangitis* - This is an autoimmune liver disease causing fatigue and pruritus, but it is not part of the common **autoimmune polyendocrine** clusters. - It would typically show an elevated **alkaline phosphatase (ALP)** and is associated with anti-mitochondrial antibodies, which are not suggested here. *Sjögren's syndrome* - While it causes fatigue and dry skin (though usually dry eyes/mouth), it is a **connective tissue disorder** rather than an organ-specific endocrine autoimmune disease. - It does not carry the same risk of acute medical collapse as undiagnosed adrenal insufficiency in a patient with polyendocrinopathy.
Question 108: A 41-year-old man presents with a 12-week history of fatigue, night sweats, and a 5kg weight loss. He reports intermittent fevers but has not documented his temperature. He travelled to India 6 months ago to visit family. Examination reveals palpable cervical lymphadenopathy measuring 2cm. Blood tests show Hb 118 g/L, WCC 9.8 × 10⁹/L (lymphocytes 6.2 × 10⁹/L), ESR 48 mm/hr, CRP 35 mg/L, normal liver and renal function. Chest X-ray shows bilateral hilar lymphadenopathy. What is the single most appropriate investigation to establish the diagnosis?
- A. Mantoux test and interferon-gamma release assay
- B. CT chest with contrast and CT-guided lung biopsy
- C. Excision biopsy of cervical lymph node (Correct Answer)
- D. Bone marrow aspirate and trephine biopsy
- E. Serum ACE level and 24-hour urinary calcium
Explanation: ***Excision biopsy of cervical lymph node***- The patient presents with **B symptoms** (fatigue, night sweats, weight loss, fevers), **palpable cervical lymphadenopathy**, and **bilateral hilar lymphadenopathy** on CXR, with a travel history to **India**.- An **excision biopsy** is the **gold standard** for investigating accessible peripheral lymphadenopathy, providing sufficient tissue for **histological examination**, **immunohistochemistry**, and **microbiological cultures** (e.g., for TB) to definitively diagnose conditions like **lymphoma**, **tuberculosis**, or **sarcoidosis**.*Mantoux test and interferon-gamma release assay*- These tests screen for **tuberculosis infection** (latent or active) but cannot differentiate it from other serious conditions like **lymphoma** or **sarcoidosis**, which are also in the differential given the B symptoms and lymphadenopathy.- A positive result does not provide **histological confirmation**, which is essential for a definitive diagnosis and treatment planning in this clinical scenario.*CT chest with contrast and CT-guided lung biopsy*- While **bilateral hilar lymphadenopathy** is evident, performing a **CT-guided lung biopsy** is a more **invasive procedure** with higher risks (e.g., **pneumothorax**) compared to biopsying an accessible peripheral lymph node.- This investigation is generally reserved for situations where peripheral nodes are not accessible or a specific lung lesion needs to be targeted, which is not the case here given the 2cm cervical node.*Bone marrow aspirate and trephine biopsy*- This investigation is primarily used for **staging hematological malignancies** (e.g., lymphoma) or diagnosing **disseminated infections**, rather than as a primary diagnostic step for palpable superficial lymphadenopathy.- While it could show involvement in **lymphoma** or **disseminated TB**, it is usually not the first-line investigation when a more accessible lymph node is available for direct sampling.*Serum ACE level and 24-hour urinary calcium*- **Serum ACE** is a non-specific marker for **sarcoidosis** with variable sensitivity and specificity, and it cannot rule out other critical diagnoses like **lymphoma** or **tuberculosis**.- Elevated **urinary calcium** can support sarcoidosis but, like ACE, these biochemical tests do not provide the **definitive tissue diagnosis** required to establish the underlying cause of the patient's symptoms and lymphadenopathy.
Question 109: A 58-year-old woman presents with a 10-week history of unintentional weight loss of 8kg. She reports decreased appetite but denies dysphagia, abdominal pain, or altered bowel habit. She has no past medical history and takes no regular medications. Physical examination is unremarkable. Initial blood tests show Hb 132 g/L, WCC 7.2 × 10⁹/L, platelets 245 × 10⁹/L, ESR 18 mm/hr, CRP 6 mg/L, normal renal and liver function, normal thyroid function, and HbA1c 38 mmol/mol. What is the most appropriate next step in management?
- A. Arrange urgent upper and lower gastrointestinal endoscopy within 2 weeks
- B. Arrange CT chest, abdomen and pelvis with contrast (Correct Answer)
- C. Repeat blood tests in 4 weeks and review weight trajectory
- D. Arrange psychiatric assessment for possible depression or eating disorder
- E. Request tumour markers including CA-19-9, CEA, and CA-125
Explanation: ***Arrange CT chest, abdomen and pelvis with contrast*** - In a 58-year-old woman with significant **unexplained weight loss** (8kg in 10 weeks) and decreased appetite, a **CT chest, abdomen, and pelvis (CT CAP)** is the most appropriate first-line investigation to screen for occult malignancy. - This comprehensive imaging allows for the detection of potential primary tumors or metastases in various common sites (e.g., lung, pancreas, kidney, ovary) when initial blood tests are normal and localizing symptoms are absent. *Arrange urgent upper and lower gastrointestinal endoscopy within 2 weeks* - These invasive procedures are typically indicated for patients with specific **gastrointestinal symptoms** such as dysphagia, abdominal pain, altered bowel habit, or iron-deficiency anemia. - In the absence of such localized symptoms, a **cross-sectional imaging study** like CT CAP provides a broader and more efficient initial screening for systemic causes of weight loss. *Repeat blood tests in 4 weeks and review weight trajectory* - Delaying further investigation of **significant unintentional weight loss** in an older adult is unsafe and may lead to a missed or delayed diagnosis of a serious underlying condition, such as malignancy. - Since initial comprehensive blood tests were unremarkable and did not reveal a cause, repeating them without further advanced imaging is an inadequate approach when **urgent cancer screening** is warranted. *Arrange psychiatric assessment for possible depression or eating disorder* - While psychiatric conditions can cause weight loss, in a patient of this age with significant unexplained weight loss, an **organic cause**, particularly malignancy, must be thoroughly investigated and ruled out first. - Psychiatric diagnoses should generally be considered **diagnoses of exclusion** after a comprehensive medical workup has failed to identify a physical etiology, especially in a patient with no prior psychiatric history. *Request tumour markers including CA-19-9, CEA, and CA-125* - **Tumor markers** generally lack the sensitivity and specificity for routine cancer screening in individuals with undifferentiated symptoms and can result in false positives or negatives. - Their primary utility lies in monitoring response to treatment, detecting recurrence in known cancers, or for specific diagnostic situations, not as a first-line investigation for **unexplained weight loss**.
Question 110: Which of the following statements best describes the concept of 'diagnostic safety-netting' when managing patients with undifferentiated symptoms in primary care?
- A. Providing clear written information about red flag symptoms and arranging definite follow-up with specific review criteria (Correct Answer)
- B. Arranging multiple baseline investigations to exclude serious pathology before discharge
- C. Referring all patients with unexplained symptoms to secondary care for specialist assessment
- D. Prescribing empirical treatment and reviewing response after 4 weeks
- E. Documenting in notes that the patient should return if symptoms worsen
Explanation: ***Providing clear written information about red flag symptoms and arranging definite follow-up with specific review criteria*** - **Diagnostic safety-netting** is a core clinical skill used to manage **diagnostic uncertainty** by empowering patients with specific **red flag symptoms** that require urgent re-evaluation. - It involves a structured plan that includes **time-based** or **symptom-based** follow-up, ensuring that serious pathology is not missed if symptoms evolve. *Arranging multiple baseline investigations to exclude serious pathology before discharge* - This approach may lead to **over-investigation**, unnecessary patient anxiety, and increased healthcare costs without clinical justification. - **Safety-netting** is designed specifically for cases where immediate investigation is not yet warranted but monitoring is essential. *Referring all patients with unexplained symptoms to secondary care for specialist assessment* - Routine **specialist referral** for all undifferentiated symptoms is unsustainable and often unnecessary, as many symptoms resolve spontaneously in **primary care**. - Primary care clinicians use **watchful waiting** alongside safety-netting to differentiate between minor illness and significant pathology. *Prescribing empirical treatment and reviewing response after 4 weeks* - **Empirical treatment** can mask worsening symptoms and potentially delay the diagnosis of a more serious underlying condition. - A fixed **4-week review** may be too late if the patient experiences a rapid decline or develops acute **red flag** indicators. *Documenting in notes that the patient should return if symptoms worsen* - Simply telling a patient to return "if symptoms worsen" is considered **vague safety-netting** and is often inadequate for patient safety. - Effective safety-netting must be **specific** regarding what "worsening" looks like and provide a definitive **follow-up mechanism**.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free